Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.Business Expertise: Company is in production and oral formulation of different proteins using TrabiORAL technology a) Oncology b) Auto Immunity c) Drug Delivery d) Biogenerics
TRANSGENE BIOTEK LIMITED has published its financial results for the quarter ended June 30, 2026. The company reported total income from operations of 6.00 and a net loss after tax of -38.90. Basic and diluted earnings per share stood at Rs. -0.05. These results, which consolidate subsidiary figures, were reviewed...
Unaudited Financial Results for the quarter ended 30th June 2026.
Transgene Biotek's board approved Q1 FY27 standalone and consolidated results: revenue at ₹0.06 Cr, net loss at ₹0.39 Cr. They also extended the AGM date and appointed M/s. Manisha Dubey & Associates as new Internal Auditors for FY26-27.
Transgene Biotek Ltd has announced a board meeting on August 07, 2026. The board will consider the Q1 FY27 financial results and discuss seeking an extension for its FY25-26 AGM. An internal auditor appointment is also on the agenda.
